Chronic lymphocytic leukemia and renal cell carcinoma: literature review and case reports

Renal cell carcinoma which had acceded to the CLL, induces the progression of lymphatic tumours and contributes to the rapid development of renal failure. The surgical removal of the affected renal not eliminates the progression of CLL. Monotherapy by alkylating agents is not effective, while bendamustine therapy allows to reach the positive result.

• B.T. Dzhumabaeva FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр МЗСР РФ», Москва, Российская Федерация
• E.A. Nikitin FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр МЗСР РФ», Москва, Российская Федерация
• I.B. Kaplanskaya FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр МЗСР РФ», Москва, Российская Федерация
• E.E. Zybunova FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр МЗСР РФ», Москва, Российская Федерация
• L.S. Biryukova FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр МЗСР РФ», Москва, Российская Федерация

1. Manusow D., Weinerman B.H. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267–9. DOI: https://doi.org/10.1001/jama.1975.03250030023012
2. Santoro A., Rilke F., Franchi F. et al. Primary malignant neoplasms associated with chronic lymphocytic leukemia. Tumori 1980; 66: 431–7. DOI: https://doi.org/10.1177/030089168006600404
3. Mellemgaard A., Geisler C.H., Storm H.H. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia. Eur. J. Haematol. 1994; 53: 218–27. DOI: https://doi.org/10.1111/j.1600-0609.1994.tb00192.x
4. Molica S., Alberti A. Second neoplasms in chronic lymphocytic leukemia: analysis of incidence as a function of the length of follow-up. Haematologica 1989; 74(5): 481–5.
5. Kyasa M.J., Hazlett L., Parrish R.S., Schichman S.A., Zent C.S. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk. Lymphoma 2004; 45: 507–13. DOI: https://doi.org/10.1080/10428190310001612939
6. Greene M.H., Hoover R.N., Fraumeni J.F. et al. Subsequent cancer in patients with chronic lymphocytic leukemia— a possible immunologic mechanism. J. Natl. Cancer Inst. 1978; 61: 337–40.
7. Hisada M., Biggar R.J., Greene M.H. et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979–81. DOI: https://doi.org/10.1182/blood.V98.6.1979
8. Mauro F.R., Foa R., Giannarelli D. et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999; 94: 448–54. DOI: https://doi.org/10.1182/blood.V94.2.448.414k13_448_454
9. Suzuki K., Maekawa I., Mikuni C. et al. Prognosis in 75 cases of chronic lymphocytic leukemia and second malignancies. Rinsho Ketsueki. 1997; 38: 740–4.
10. Parekh K., Rusch V., Kris M. The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia. Cancer 1999; 86: 1720–3. DOI: https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1720::AID-CNCR13>3.3.CO;2-O
11. Pigeaud-Klessens M.L., van der Valk P. Multiple neoplasms: a case report. Orbit. 2002; 21: 145–8. DOI: https://doi.org/10.1076/orbi.21.2.145.7193
12. Prosvic P., Dulicek P., Odrazka K. et al. Asynchronous occurrence of three neoplastic diseases: chronic B-cell lymphatic leukemia, renal carcinoma and prostatic adenocarcinoma. Chir. 2003; 82: 583–6.
13. Тravis L.B., Curtis R.E., Boice J.D. et al. Second cancers following non-Hodgkin’s lymphoma. Cancer 1991; 67: 2002–9. DOI: https://doi.org/10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E
14. Travis L.B., Curtis R.E., Glimelius B. et al. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J. Natl. Cancer Inst. 1993; 85: 1932–7. DOI: https://doi.org/10.1093/jnci/85.23.1932
15. Anderson C.M., Puszatai L., Palmer J.L., Cabanillas F. Coincidental renal cell carcinoma and non-Hodgkin’s lymphoma: the M. D. Anderson experience and review of literature. J. Urol. 1998; 159: 714–6. DOI: https://doi.org/10.1016/S0022-5347(01)63708-X
16. Sendi P., Schonenberger A., Bargetzi M. Chronic lymphocytic leukemia and loss of strength in the right arm—not a typical combination. Praxis (Bern 1994). 2007; 96(18): 729–32. DOI: https://doi.org/10.1024/1661-8157.96.18.729
17. Kunthur A., Wiernik P.H., Dutcher J.P. Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature. Am. J. Hematol. 2006; 81(4): 271–80. DOI: https://doi.org/10.1002/ajh.20533
18. Deeb R., Zhang Z., Ghanem T. Metastatic renal cell carcinoma to the parotid gland in the setting of chronic lymphocytic leukemia. Case Report Med. 2012 Feb 19. DOI: https://doi.org/10.1155/2012/265708
19. Sampalo A., Navas G., Medina F. et al. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000; 96: 3168–74. DOI: https://doi.org/10.1182/blood.V96.9.3168.h8003168_3168_3174
20. Orfao A., Gonzalez M., San Miguel J.F. et al. Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia. Haematologia (Budap.) 1990; 23: 49–56.
21. Varan A., Buyukpamukcu M., Ersov F. et al. Malignant solid tumors associated with congenital immunodeficiency disorders. Pediatr. Hematol. Oncol. 2004; 21: 441–51. DOI: https://doi.org/10.1080/08880010490457231
22. Perri R.T., Kay N.E. Abnormal T cell function in early-stage chronic lymphocytic leukemia (CLL) patients. Am. J. Hematol. 1986; 22: 55–61. DOI: https://doi.org/10.1002/ajh.2830220109
23. Piszcz J., Oleksiuk J., Kloczko J. Gastric cancer in chronic lymphocytic leukaemia patient. Pol. Arch. Med. Wewn. 2005; 114: 1217–9.
24. Hsu C.W., Krevsky B., Sigman L.M. et al. Rapid progression of Barrett’s esophagus to metastatic esophageal carcinoma in a patient with chronic lymphocytic leukemia. J. Clin. Gastroenterol. 1998; 27: 261–4. DOI: https://doi.org/10.1097/00004836-199810000-00019
25. Brown J.R., Freedman A.S. Secondary solid tumors after autologous bone marrow transplantation in non-Hodgkin’s lymphoma. Am. J. Oncol. Rev. 2005; 4: 530–3.
26. Morra E., Nosari A., Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol. Cell Ther. 1999; 41: 145–51. DOI: https://doi.org/10.1007/s00282-999-0145-0
27. Cheson B.D., Vena D.A., Barrett J. et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J. Clin. Oncol. 1999; 17: 2454–60. DOI: https://doi.org/10.1200/JCO.1999.17.8.2454
28. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Lymphoma 2004; 45: 205–19. DOI: https://doi.org/10.1080/1042819031000139666
29. Callea V., Brugiatelli M., Stelitano C. et al. Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Lymphoma. 2006; 47: 2314–20. DOI: https://doi.org/10.1080/10428190600880977
30. Van , Laneuville P., MacDonald D. et al. A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Curr. Oncol. 2012; 19(3): 160–8. DOI: https://doi.org/10.3747/co.19.1064